ibrutinib,venetoclax,Obinutuzumab
roche,janssen,abbvie
['cll13', 'equate', 'cll', 'fil,veral,12', 'gaia']
congress | #ash22 henriette huber presented the final analysis of the cll2-give trial of pts with cll with del(17p) and/or tp53 mutation. the triple combination treatment regimen used had an acceptable safety profile with a 36 month os rate of 92.6%.
#medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm